ESSA Pharma Inc.根据不列颠哥伦比亚省法律于2009年1月6日注册成立。该公司是一家处于发展阶段的制药公司,专注于小分子药物的开发以治疗阉割性前列腺癌(“CRPC”)。该公司正在开发的药物是选择性阻断雄激素受体(“AR”)的氨基末端结构域(“NTD”),能够潜在地克服CRPC的已知AR - 依赖性机制,从而使CRPC患者病情不恶化,提高生存率。
董事
名称
职位
David Parkinson
President, Chief Executive Officer and Director
Richard M. Glickman
Chairman of the Board
Alex Martin
Director
Franklin Berger
Director
Gary Sollis
Director
Lauren Merendino
Director
Marella Thorell
Director
Philip Kantoff
Director
Sanford Zweifach
Director
Scott Requadt
Director
股东
名称
职位
David Parkinson
President, Chief Executive Officer and Director
Peter Virsik
Executive Vice President and Chief Operating Officer